Home / Centerstage / 2019 / june / Week 2 /
Pfizer agrees to acquire Array BioPharma for $10.64 billion in cash, expanding its cancer drug portfolio with targeted therapies. The deal highlights the significance of the cancer drug market for pharmaceutical companies. Pfizer aims to tap into the growing market for genetic-based cancer treatments, with Array's drugs Braftovi and Mektovi showing promise in treating specific patients. This strategic move aligns with Pfizer's goal of strengthening its presence in the lucrative oncology sector.
Sunday, 16 June, 2019